Human Psychopharmacology: Clinical and Experimental This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Is there a potential of misuse for Magnolia officinalis compounds/metabolites?
ConclusionsTo the best of our knowledge, this is the first paper commenting on the possible Magnolia derivatives' potential of misuse. Magnolia's recent increase in popularity, mainly as a sedative, may be arguably due to its peculiar pharmacological properties/acceptable affordability levels/virtually worldwide favorable legal status and customers' attraction to a product being perceived as “natural” and hence somehow “safe.” Future/potent/synthetic magnolol and honokiol structural analogues could however contribute to increasing the number of synthetic GABA‐ergic/cannabimimetic misusing compounds. (Source: Huma...
Source: Human Psychopharmacology: Clinical and Experimental - May 18, 2017 Category: Psychiatry Authors: Fabrizio Schifano, Valentina Guarino, Duccio G. Papanti, Jacopo Baccarin, Laura Orsolini, John M. Corkery Tags: SPECIAL ISSUE ON NOVEL PSYCHOACTIVE SUBSTANCES Source Type: research

The dose –effect relationship of baclofen in alcohol dependence: A 1‐year cohort study
ConclusionThe relationship between dose of baclofen and favorable drinking outcome was U‐shaped, that is, was increased at low and high doses compared to medium doses. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - May 18, 2017 Category: Psychiatry Authors: Baptiste Pignon, Julien Labreuche, Marine Auffret, Sophie Gautier, Sylvie Deheul, Nicolas Simioni, Olivier Cottencin, R égis Bordet, Alain Duhamel, Benjamin Rolland Tags: RESEARCH ARTICLE Source Type: research

A matter of life and death: substance ‐caused and substance‐related fatalities in Ibiza in 2015
ConclusionsAlthough the use of NPS is rapidly increasing in Europe, according to the results from our sample, alcohol and well‐known stimulants (MDMA and cocaine) are still the substances of abuse mainly involved in the cases of substance‐caused and substance‐related fatalities. The significant increase of fatalities in Ibiza in the last 5 years is an issue that must be taken into account and should be better investigated, as other theories besides NPS‐increased diffusion should be proposed, and therefore, targeted prevention strategies should be designed. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - May 18, 2017 Category: Psychiatry Authors: Rita Santacroce, Claudia Ruiz Bennasar, Juan Ramon Sancho Jaraiz, Federica Fiori, Fabiola Sarchione, Federica Angelini, Gabriella Catalano, Maria Luisa Carenti, John Martin Corkery, Fabrizio Schifano, Massimo Di Giannantonio, Giovanni Martinotti Tags: SPECIAL ISSUE ON NOVEL PSYCHOACTIVE SUBSTANCES Source Type: research

Novel psychoactive substances (NPS) use in severe mental illness (SMI) patients: Potential changes in the phenomenology of psychiatric diseases
ConclusionsNPS use could modify clinical features of SMI, but these conclusions cannot be generalizable. More evidence is needed to establish the causal and effective connection between NPS use and course of illness, type of psychiatric symptoms, and outcome of treatment in terms of adherence or response. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - May 18, 2017 Category: Psychiatry Authors: Giuseppe Bersani, Elisabeth Prevete Tags: SPECIAL ISSUE ON NOVEL PSYCHOACTIVE SUBSTANCES Source Type: research

L ‐carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double‐blind study
ConclusionL‐carnosine results in significant reduction of obsessive‐compulsive symptoms when used as an adjuvant to fluvoxamine. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - May 8, 2017 Category: Psychiatry Authors: Somaye Arabzadeh, Maryam Shahhossenie, Bita Mesgarpour, Farzin Rezaei, Mohammad Reza Shalbafan, Zahra Ghiasi, Shahin Akhondzadeh Tags: RESEARCH ARTICLE Source Type: research

Biomarkers of the alcohol hangover state: Ethyl glucuronide (EtG) and ethyl sulfate (EtS)
ConclusionsAlthough urine EtG and EtS concentration did not significantly correlate to estimated peak blood alcohol concentrations or the number of alcoholic drinks consumed, a significant correlation was found with urine ethanol concentration. However, urine EtG and EtS concentrations did not significantly correlate with overall hangover severity. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - May 1, 2017 Category: Psychiatry Authors: Marlou Mackus, Aurora J. A. E. Loo, S. Jorinde Raasveld, Anna Hogewoning, Javier Sastre Tora ño, Frits M. Flesch, Gerdien A. H. Korte‐Bouws, Renier H. P. Neer, Xiaochun Wang, Thomas T. Nguyen, Karel A. Brookhuis, Aletta D. Kraneveld, Johan Garssen, Jor Tags: RESEARCH ARTICLE Source Type: research

Open ‐label, proof‐of‐concept study of brexanolone in the treatment of severe postpartum depression
ConclusionsBrexanolone was well tolerated and demonstrated activity in severe PPD. Larger, double‐blind trials are needed for further evaluation. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - March 30, 2017 Category: Psychiatry Authors: Stephen J. Kanes, Helen Colquhoun, James Doherty, Shane Raines, Ethan Hoffmann, David R. Rubinow, Samantha Meltzer ‐Brody Tags: SHORT COMMUNICATION Source Type: research

Prescribing in schizophrenia and psychosis: Increasing polypharmacy over time
ConclusionIn conclusion, we determined an increase in psychotropic polypharmacy over the follow‐up period. Body mass index or fasting blood glucose increased over time. Clozapine and depot antipsychotic prescriptions were often not recorded in the general practitioner records. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - March 30, 2017 Category: Psychiatry Authors: Adrian Heald, Mark Livingston, Alison Yung, M.A. De Hert Tags: RESEARCH ARTICLE Source Type: research

Pharmacotherapy effectiveness for clinical subgroups among children and adolescents with early onset schizophrenia
ConclusionsRegardless of the specific constellation of symptoms and comorbid disorders targeted, the coprescription of multiple SGAs was not effective over time in stabilizing children and adolescents outside of acute care settings. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - March 30, 2017 Category: Psychiatry Authors: Jeanette M. Jerrell, Roger S. McIntyre, Chelsea B. Deroche Tags: RESEARCH ARTICLE Source Type: research

Diagnostic clusters associated with an early onset schizophrenia diagnosis among children and adolescents
ConclusionSymptom patterns plus age of first diagnosis are important differentiators of EOS subgroups in this cohort. Earlier recognition of psychiatric symptom/syndrome patterns that frequently co‐occur may enable clinicians to stratify/tailor treatment interventions. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - March 30, 2017 Category: Psychiatry Authors: Jeanette M. Jerrell, Roger S. McIntyre, Chelsea B. Deroche Tags: RESEARCH ARTICLE Source Type: research

Long ‐term antipsychotic use and brain changes in schizophrenia – a systematic review and meta‐analysis
ConclusionsAntipsychotic medication may associate with brain structure changes. More long‐term follow‐up studies taking into account illness severity measures are needed to make definitive conclusions. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - March 30, 2017 Category: Psychiatry Authors: Sanna Huhtaniska, Erika J ääskeläinen, Noora Hirvonen, Jukka Remes, Graham K. Murray, Juha Veijola, Matti Isohanni, Jouko Miettunen Tags: REVIEW ARTICLE Source Type: research

Issue Information
No abstract is available for this article. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - March 30, 2017 Category: Psychiatry Tags: ISSUE INFORMATION Source Type: research

The detection and prevention of unintentional consumption of DOx and 25x ‐NBOMe at Portugal's Boom Festival
ConclusionsAlthough these results support the provision of integrated drug‐checking services in party settings, evidence of their utility and effectiveness would be improved through future research incorporating more robust measures of outcomes following provision of drug‐checking results. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - March 1, 2017 Category: Psychiatry Authors: Daniel Martins, Monica J. Barratt, Cristiana Vale Pires, Helena Carvalho, Mireia Ventura, Iv án Fornís, Helena Valente Tags: SPECIAL ISSUE ON NOVEL PSYCHOACTIVE SUBSTANCES Source Type: research

The effects and toxicity of cathinones from the users' perspectives: A qualitative study
ConclusionsThe Internet discussion forums provide useful sources of information regarding the effects and toxicity of cathinones, which can be taken into account when assessing the safety of drugs. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - March 1, 2017 Category: Psychiatry Authors: Sulaf Assi, Nargilya Gulyamova, Paul Kneller, David Osselton Tags: SPECIAL ISSUE ON NOVEL PSYCHOACTIVE SUBSTANCES Source Type: research

Profile, effects, and toxicity of novel psychoactive substances: A systematic review of quantitative studies
ConclusionsDespite the unique subjective effects associated with the use of NPS, harmful effects could be severe and/or lethal. Therefore, there is a need to develop research in the area of NPS and promote awareness among healthcare professionals. (Source: Human Psychopharmacology: Clinical and Experimental)
Source: Human Psychopharmacology: Clinical and Experimental - March 1, 2017 Category: Psychiatry Authors: Sulaf Assi, Nargilya Gulyamova, Kinda Ibrahim, Paul Kneller, David Osselton Tags: SPECIAL ISSUE ON NOVEL PSYCHOACTIVE SUBSTANCES Source Type: research